HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Vol 20, No 12, December 2016 – Medical Imaging Technology       » Climate Change Could Hurt Coffee, Help Banana Production       » Partnerships and Innovation: Shaping the Future of Healthcare in Asia Pacific       » Chugai's Novel Antibody Technologies Put Singapore at the Centre of Fight Against Disease       » NUS Scientists Discover the "Switch" that Makes Breast Cancer Cells Aggressive      
EYE ON CHINA
Charles River Laboratories to expand research models business in China
Charles River Laboratories International Inc. has announced that it has entered into an agreement to acquire 75% ownership of Vital River, the premier commercial provider of research models and related services in China. Through this acquisition, Charles River will provide high-quality research models and associated services to the emerging China market for drug discovery and development. The acquisition is expected to close in the first quarter of 2013, subject to customary closing conditions, including Chinese regulatory approvals.

James C. Foster, Chairman, President, and Chief Executive Officer of Charles River Laboratories, commented, “We expect demand for research models in China to significantly increase over the next several years as drug development initiatives in academia, government and biopharmaceutical companies expand. Through our acquisition of Vital River, Charles River intends to set the standards for research models in China, the third-largest pharmaceutical market in the world, and play a leading role in this emerging opportunity.”

For the last ten years, Vital River has been a licensee for production and distribution of Charles River research models in China, with sites which reflect Charles River facility design.

Charles River expects to acquire the 75% ownership of Vital River for approximately $27 million, subject to certain closing adjustments. The transaction is expected to add more than 1% to 2013 total net sales on a full-year basis and be slightly accretive to 2013 earnings per share. When the acquisition is completed, Vital River will be majority owned and controlled by Charles River. The agreement provides an option for Charles River to acquire the remaining 25% of Vital River at a later date.

Click here for the complete issue.

NEWS CRUNCH  
news Accuron Technologies' MedTech Division Invests into AWAK Technologies
news Philips introduces PerformanceBridge suite of operational performance improvement software and services for radiology departments
news Give a Gift that Will Last a Lifetime this Holiday Season with Smile Train
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Lady Ganga: Nilza'S Story
COLUMNS  
Subscribe to APBN E-Newsletter
Find us under 'Others' option to receive APBN e-newsletters thrice a month!

APBN Editorial Calendar 2017
January:
Lungs & Respiratory System
February:
Cancer Research, Treatment/Technology
March:
Traditional Chinese Medicines
April:
Eye Care/ Eye Health
May:
The Piece of Your Mind - Brain Health/Science
June:
Featuring Biotech Start-Ups/Companies
July:
Food Science & Technology
August:
Diabetics Technology
September:
No. 1 Killer - Heart Diseases, Diagnosis and Treatment
October:
Skin Diseases/Allergic Reactions
November:
Diseases threatening our Children
December:
Liver Health & Treatment/Technology
Editorial calendar is subjected to changes.
– Editor: Carmen, Jia Wen Loh
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Carmen
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2016 World Scientific Publishing Co Pte Ltd  •  Privacy Policy